We’ve released new content on stem cell markets that we are excited to share with you. Let me know what you think?
CellPlan Launches The World’s First Global Stem Cell Healthcare Plan
CellPlan today announced the creation of the world’s first global stem cell healthcare plan, which will be launched at the World Cord Blood Congress Europe 2016 in London this month. The UK company said that the new medical insurance product could revolutionize stem cell healthcare by making stem cell transplants affordable for families who require treatment for life threatening diseases.
Axiogenesis Secures Funding for Market Expansion from Sino-German High-Tech Fund
Founded in 2001 and headquartered in Cologne, Germany, Axiogensis specializes in induced pluripotent stem cell (iPSC) products, including in vitro models of healthy and diseased cell types. This week, Axiogenesis announced a major investment from the Sino-German High-Tech Fund, which will assist Axiogenesis with expanding product development, improving its disease modeling capabilities, and accelerating the introduction of Axiogenesis products into high-yield market segments, including the pharmaceutical and chemical sectors.
Commercial Momentum Accelerates as Cynata Enters License Option Agreement with apceth GmbH & Co. KG
Cynata announced it has entered into a worldwide license option agreement with apceth GmbH & Co. KG for the use of Cynata’s unique Cymerus technology in combination with genetic modification technologies designed to open up prospective new therapeutic fields to MSCs, particularly the treatment of cancer. The agreement provides for an immediate upfront cash payment to Cynata, followed by a series of success-based milestones, which could potentially total more than AUS $40M.
In this interview with Gregory Block, VP of Business Development for Universal Cells, Mr. Block explains how Universal Cells is creating stem cells that are universally compatible. Universal Cells’ intellectual property is exclusively in-licensed from the University of Washington and includes methods for genome editing in human stem cells via homologous recombination with recombinant adeno-associated virus (rAAV) vectors, as well as specific HLA-engineering strategies.
UK-based Thorn Medical Acquires Grand Bahama’s Okyanos to Create World-Class Stem Cell Centre
Thorn Medical PLC, an international healthcare group, announces the acquisition of Okyanos Holding Company Ltd., the leading stem cell therapy centre based in the Bahamas. Okyanos is fully licensed to provide stem cell based treatments for cardiovascular, lung and autoimmune diseases, as well as for orthopedic and urological conditions, neurological disorders and chronic wounds and tissue ischemia. The merger will expand the clinic’s services and make it one of the world’s leading centers for stem cell therapy.
Guest Post: Regulatory Oversight of Cord Blood Banking within the Ukraine
This is a guest post written by the Association of Cryobanks of Cord Blood and Other Human Tissues and Cells, a Ukraine association that brings together cord blood banks and specialized cryobanks that store biological material, including stem cells from umbilical cord blood, bone marrow, reproductive cells and tissues. Ukraine is famous for achievements in the field of cryobiology, but the Ukrainian cord blood banking industry has emerged and developed differently than within other European countries.
Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report
There is incredible enthusiasm and investment driving growth of the iPSC sector, with recent years seeing advances in clinical research applications, production and differentiation technologies, and biobanking of iPSCs. This 175-page global strategic report explores trend rate data for iPSC scientific publications, grants, patents, clinical trials, new market entrants, and more. A distinctive feature of this report is an end-user survey of 273 researchers (131 U.S. / 143 International) that identify as having induced pluripotent stem cells as a research focus.
Be Great,
Cade President/CEO of BioInformant.com
“1st and Only Market Research Firm to Specialize in the Stem Cell Industry”
Want to be better informed than your competition? Get future stem cell industry updates.
About BioInformant
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.